Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021937 · ClinicalTrials.gov registry record · Phase 3
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
A Phase 3 study, sponsored by University of Colorado, Denver.
- Not yet
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT07021937 is a Phase 3 study that has not yet begun recruiting, run by University of Colorado, Denver. The registered enrollment target is 120 participants.
The verdict
NCT07021937, a Phase 3 study, has not yet begun recruiting, sponsored by University of Colorado, Denver.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
Interventions
- DRUG Placebo
- DRUG Semaglutide 1.7mg subcutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2031-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07021937
The ClinicalTrials.gov registry entry for NCT07021937 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07021937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07021937 about?
NCT07021937 is a clinical study titled "Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity". Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible f...
What is the current status of trial NCT07021937?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2026-06-15. Estimated completion is 2031-04-30.
What interventions are being tested in trial NCT07021937?
The interventions under investigation include: Placebo (DRUG), Semaglutide 1.7mg subcutaneous (DRUG).
Who is sponsoring clinical trial NCT07021937?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.